Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Dementia in 2013

Frontotemporal lobar degeneration—building on breakthroughs

Nature Reviews Neurology volume 10, pages 70–72 (2014)Cite this article

Subjects

Genetic research in frontotemporal lobar degeneration (FTLD) is gaining momentum. Following the discovery of a repeat expansion in the gene C9 open reading frame 72 (C9orf72), three major genes and associated disease mechanisms and inclusion body pathologies have emerged, paving the way for personalized medicine in FTLD.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Three subtypes of frontotemporal lobar degeneration.

References

  1. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256 (2011).

    Article  CAS  Google Scholar 

  2. Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268 (2011).

    Article  CAS  Google Scholar 

  3. Gijselinck, I. et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet 11, 54–65 (2012).

    Article  CAS  Google Scholar 

  4. Cruts, M., Gijselinck, I., Van Langenhove, T., van der Zee, J. & Van Broeckhoven, C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 36, 450–499 (2013).

    Article  CAS  Google Scholar 

  5. van der Zee, J. et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat. 34, 363–373 (2013).

    Article  CAS  Google Scholar 

  6. Dols-Icardo, O. et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum. Mol. Genet. http://dx.doi.org/10.1093/hmg/ddt460.

  7. Van Langenhove, T. et al. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol. 70, 365–373 (2013).

    Article  Google Scholar 

  8. Mori, K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335–1338 (2013).

    Article  CAS  Google Scholar 

  9. Mackenzie, I. R. et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 126, 859–879 (2013).

    Article  CAS  Google Scholar 

  10. Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530–E4539 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank J.-J. Martin and A. Sieben for the immunohistochemistry images and expert support. The authors receive funding from the Belgian Science Policy Office Interuniversity Attraction Poles programme, the European Centers of Excellence in Neurodegeneration, the Methusalem Excellence programme, the Alzheimer Research Foundation, the Medical Foundation Queen Elisabeth, the Research Foundation Flanders, the Agency for Innovation by Science and Technology Flanders, the University of Antwerp Research Fund, and the MetLife Foundation Award for Medical Research.

Author information

Authors and Affiliations

  1. Department of Molecular Genetics, Neurodegenerative Brain Diseases Group, VIB and Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, Antwerp, B-2610, Belgium

    Julie van der Zee & Christine Van Broeckhoven

Authors
  1. Julie van der Zee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Van Broeckhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Van Broeckhoven.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Zee, J., Van Broeckhoven, C. Frontotemporal lobar degeneration—building on breakthroughs. Nat Rev Neurol 10, 70–72 (2014). https://doi.org/10.1038/nrneurol.2013.270

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.270

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing